INTRODUCTION
In order to improve the bioavailability of poorly water-soluble drugs, an increasing number of pharmaceutical formulation technologies are being established to address this challenge of drug product development. These include micronization, 1 formation of complexes 2 and solid dispersions, etc. 3, 4 The therapeutic usage of solid dispersions has been the focus of many recent studies, 5, 6 and several successful examples have been commercialized in pharmaceutical market. In solid dispersions drug molecules or very fine drug crystals are dispersed in a biocompatible or water-soluble matrix. A number of watersoluble polymers such as hydroxypropylcellulose, hydroxypropyl methylcellulose (HPMC), polyethylene glycol (PEG), and poly(vinylpyrrolidone) (PVP) have been used as carriers for solid dispersions. [7] [8] [9] Conventionally, solid dispersions are prepared by fusion method and solvent evaporation. 10 Fusion method, also called melt method, is precluded for many situations because of its high processing temperature, usually about 150°C, at which many active pharmaceutical ingredients (APIs) already start decomposition; On the other hand, solvent evaporation method avoids the difficulties encountered with fusion method by working at milder conditions. However, excess usage of organic solvents and complication of product purity during the processing still hamper the application of solvent evaporation techniques. Among many derivatives of solvent evaporation method, spray drying technique has been proven a powerful tool for preparing solid dispersions of drug and polymers 11, 12 because of its simplicity and effectiveness. While further improvement is needed to make this technique sufficiently practical, alternative technologies are under development in pursuit of high product quality and low environmental impact. Glibenclamide is a second generation sulphonylurea and oral hypoglycemic agent used for the management of diabetes mellitus. It causes hypoglycemia by stimulating release of insulin from pancreatic cells by increasing the sensitivity of peripheral tissue to insulin. It is rapidly and well absorbed but may have wide inter and intra individual variability. Micronized Glibenclamide is better absorbed and more effective at a lower dose than non-micronized form.
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MATERIAL AND METHOD Materials
Glibenclamide was obtained as a gift sample from Zee Labs, Paonta Sahib. All other chemicals were of analytical grade.
Methods
Preparation of Calibration Curve:
Stock solution A was prepared by dissolving 10 mg of pure drug in 100 mL volumetric flask and volume was made up to mark with phosphate buffer pH 7.4 1 ml of the stock solution A was taken in another volumetric flask and volume was made upto 100 ml with phosphate buffer pH 7.4 (stock solution B). Aliquots of 0.2 mL, 0.4 ml, 0.6 mL and 0.8 mL were taken from Stock Solution B and diluted upto 10ml in order to get the concentration range from 2-10 µg/mL and absorbance was noted at 237 nm using UV-VIS spectrophotometer. 16, 17 Preparation of Solid Dispersion of Glibenclamide Solid dispersions were prepared by physical mixing and fusion method. Table 1 describes the composition of various solid dispersions. Preparation of Glibenclamide-PEG physical mixture Physical mixture of Glibenclamide with the combination of PEG 4000 and PEG 1500 in different ratios obtained from design expert (8.0.5) were prepared by thoroughly mixing the accurately weighed quantity of drug and carrier in glass mortar and pestle for 5 min and sieved through a 0.25 mm sieve (#60).
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Preparation of Glibenclamide -PEG solid dispersion by fusion method Physical mixture was melt in a water bath with gradual increasing of temperature up to the value necessary for the complete melting. The molten mass was rapidly cooled with constant stirring using a glass rod. The resulting solid dispersions were stored in dessicator for 24 hrs, and then grounded in mortar for 2 min. and passed through a 0.25 mm sieve (# 60).
KANAV MIDHA et al.: Solubility enhancement for Glibenclamide
Experimental design for formulations of solid dispersion containing PEG Two independent variables, the amount of PEG 1500 (X 1 ) and PEG 4000 (X 2 ) were studied at 3 levels each. The central point (0, 0) was studied at quintuplicate. All other formulation and processing variables were kept invariant throughout the study. Table 2 , 3 and 4 summarizes an account of the 13 experimental runs studied, their factor combinations, and the translation of the coded levels to the experimental units employed during the study. Solubility percentage and percent cumulative drug release (% CDR) were taken as the response variables.
19
Characterization of Solid Dispersions
Micromeritic Properties
Various micromeritic properties were studied for prepared solid dispersions. The flow properties of SD were examined in terms of Angle of repose, Bulk density, Tapped density, Carr's index and Hausner's ratio. 20, 21 Solubility Studies The solubility of glibenclamide was determined in different solvents system (particularly phosphate buffer pH 7.4 and distilled water). An excess quantity of the drug was mixed separately with 10mL of each solvent in conical flasks and kept on shaker for 24 hours at room temperature. The solutions were analyzed spectrophotometrically at λ max 237 nm.
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Drug Content
An accurately weighed quantity of solid dispersions, equivalent to 10 mg of Glibenclamide, was transferred to 100 mL volumetric flask containing ethanol and filtered. 5 mL of filtered solution was transferred to a 50 mL volumetric flask and diluted with pH 7.4 phosphate buffer and analyzed (in triplicate) for drug content of Glibenclamide. 
Differential Scanning Calorimetry (DSC)
The DSC thermograms of pure drug (glibenclamide) was carried out to investigate any possible interaction between the drug and the utilized polymers. DSC analyses were performed using a Mettler TA4000 apparatus, equipped with a DSC 25 cell.
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In-vitro dissolution studies
In-vitro dissolution of various mixtures was studied in USP dissolution apparatus II (DS 8000, Lab India) in 900 ml of phosphate buffer pH 7.4 at 37±0.5ºC as a dissolution medium. Aliquots of 5 ml each were withdrawn at specified time intervals and replaced with equal volume of fresh medium. The withdrawn aliquots were filtered and analyzed for drug content using a UV double beam visible spectrophotometer (2202, Systronics, India) at λ max 237 nm. The study was done in triplicate. Drug concentration was calculated and expressed as cumulative percent of the drug released.
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Release kinetics Release kinetics is an integral part for the development of a dosage form because if the kinetics of drug release is known, one can also established in vitro in vivo (IVIVC) correlation. Mathematical approach is one of scientific methods to optimize and evaluate the error in terms of deviation in the release profiles of formulated products during the formulation development stage. Mathematical model approach important in research and development because of its simplicity and their interrelationships may minimize the number of trials in final optimization, thereby improving the formulation development process. The dissolution profile of the optimized batch was fitted to the different kinetic models. 
Zero Order Kinetics
This model is applicable when the release rate from a system is independent upon the concentration of drug in the system.
Where, Q t = Amount of drug dissolved in time t, Q 0 = Initial amount of drug in solution, which is zero, K 0 = Zero order rate constant.
First Order Kinetics
This model is applicable when the release rate from a system is dependent upon the concentration of drug in the system.
Where, Q t = Amount of drug dissolved in time t, Q 0 = Initial amount of drug in solution, which is zero, K t = First order rate constant.
Higuchi Kinetics
This model is applicable when the release rate from a system is dependent upon the diffusion of drug from the insoluble matrix.
Where, M t = Amount of drug released at time t, M ∞ = Amount of drug released at infinite time, K H = Higuchi release rate constant expressing design variable of system.
KorsmeyerPeppas model or Power law
The drug release data as fitted to the peppas model for predicting the mechanism of drug release from the system. Where Y= experiments response; β 0 is the intercept representing the arithmetic average of all quantitative outcomes of 13 runs. Responses β 1 to β 7 are the coefficients computed from the observed experimental values of Y. X 1 and X 2 are the coded level of the independent variables. 3D response surface graphs and 2D contour plots using the output files generated.
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Numerical optimization A numerical optimization technique using the desirability approach was employed to develop a new formulation with the desired responses. An optimized formulation was developed by setting constraints on the dependent and independent variables, and the formulation developed was then evaluated for the responses properties. The resultant experimental values obtained were compared with those predicated by mathematical models generated 29, 30 
RESULTS
Preparation of Calibration Curve
The linearity of response of the drug was obtained at 2 to10 μg/ml concentrations. The calibration curve was obtained by plotting the absorbance versus the concentration data and was treated by linear regression analysis as shown in Figure 1 . Precision Precision of the method was analysed by repeatability, determined by analyzing 6 μg/ml of glibenclamide for six times the results are reported in Table 5 . Precision of the method was studied as intra-day and inter-day variations. Intraday precision was determined by analyzing 6, 8 μg/ml of glibenclamide for three times within a day. Inter-day precision was determined by analyzing same concentrations of solutions daily for three days, the results are reported in Table 6 . Validation parameters are listed in Table  7 . Thus, the method has good reproducibility with percentage relative standard deviation less than one in both intraday and interday analysis.
Characterization of Solid Dispersions
Micromeritic Properties Solid dispersion of glibenclamide was characterized for bulk density, tapped density, angle of repose. Result of the compressibility index, Hausner's ratio and angle of repose show that all materials have sufficient compressibility and flow properties and are shown in Table 8 . 
Solubility Studies
The solubility data revealed that the solubility of the drug increased in presence of these carriers. The solubility of the drug markedly increased in presence of both polymers and was found to be more in pH 7.4 phosphate buffer as compared to distilled water ( Figure 2 ) and F3 showed best results as compared to others.
Drug content
The drug content in each solid dispersion was determined by UV-spectroscopy method. The maximum percent drug content for the all formulation was found to be 99.37 percent and minimum percent drug content from the all formulation was found to be 96.45%. Formulation F3 and F13 show 99.37 % and 98.54 % drug content respectively as shown in Table 9 . ). There is also decrease in intensity of some characteristic peaks (679 cm -1 and 833 cm -1 ). The presence of additional peaks indicates that no chemical interactions occurred between drug and carrier.
Differential Scanning Calorimetry (DSC)
Glibenclamide showed a melting endotherm at 175 0 C that is slightly higher as compared to the literature value, 169 0 C that may be due to the presence of certain impurities. Figure 6 shows the DSC of the pure drug that was compared with that of the Solid Dispersions prepared with PEG 4000 and PEG 1500. A decrease in melting point of the solid dispersions was found in the solid dispersions which showed that there is interaction of Glibenclamide with the carrier molecule. 
In-vitro dissolution studies
The release of Glibenclamide from 13 formulations were plotted as cumulative percent drug release vs time in minutes as shown in Figure 7 and 8. As shown in the figures, more than 50% of the drug was dissolved out of solid dispersion in 10 min while it was just 20% in case of pure form (F4). F3 and F13 showed slightly better dissolution properties as compared to rest of the formulations which may be due to solubilizing effect of PEG 4000 in both the cases, its prevention of aggregation and agglomeration effect, and its improvement of wettability and dispersability of drug from Solid Dispersion which can result in increasing the dissolution rate of Glibenclamide.
Release kinetics
There are number of kinetic models, which describe the overall release of drug from the dosage forms, the qualitative and quantitative changes in a formulation may alter drug release profile and in vivo performance. Correlation coefficient (R 2 ) was determined for kinetic models (Zero order, First order, Higuchi, and Peppas model) as shown in Table 10 and compared with each other, the model showing the greatest Correlation coefficient ( ≈1) (Korsmeyer-Peppas model) was taken as best fit model i.e. shown in Figure 9 ,10 and 11.
Optimization of formulations using face centered central composite design (FCCCD)
Response surface methodology (RSM) for solid dispersion Response surface methodology allows understanding of the behavior of the system by demonstrating the contribution of the independent variables. An experimental design organizes the experiments in such a manner that the required information is obtained as efficiently and precisely as Table 13 . It can be observed that R 2 is high for all responses, which indicates a high degree of correlation between the experimental and predicted responses. In addition, the predicted R 2 value is in good agreement with the adjusted R 2 value, resulting in reliable models.
Mathematical Modeling
Mathematical relationships generated using multiple linear regression analysis for the studied response variables are expressed as equations given below: The polynomial equations comprise the coefficients for intercepts, firstorder main effects, interaction terms and higher order effects. The sign and magnitude of the main effects signify the relative influence of each factor on the response. Table 11 .
ANOVA-Analysis of variance
Analysis of variance of the responses (Table 12) indicated that response surface models developed for % cumulative drug release (2 hr.) and % solubility were significant and adequate, without significant lack of fit. Response surface analysis The 3-dimensional response surface plots and the corresponding contour plots for the studied response parameters, %CDR (2 hr.) and % Solubility revealed the effect of selected independent variables on various responses. Cumulative drug release (%CDR) -The polynomial equation (1) for % CDR denotes that both the coefficients X 1 and X 2 bear a positive sign. Therefore, increasing the concentration of either PEG 4000 or PEG 1500 is expected to increase the % CDR. However, the effect of PEG 4000 is more pronounced as compared to PEG 1500.This was further revealed by the response surface plots (Figure 12, 13) . Solubility (%) -The polynomial equation (2) for % Solubility denotes that both the coefficients X 1 and X 2 bear a positive sign. Therefore, increasing the concentration of either PEG 4000 or PEG 1500 is expected to increase the % solubility. However, the effect of PEG 4000 is more pronounced as compared to PEG 1500.This was further revealed by the response surface plots (Figure 14, 15 ). 
Numerical Optimization
A numerical optimization technique using the desirability approach was employed to develop a new formulation with the desired responses. The optimum formulation was selected based on the criteria of attaining maximum % cumulative drug release and optimum solubility (%). Table 14 depicts the constraints set and the solution provided by the software.
CONCLUSION
In the present study it can be concluded that the release was directly proportional to the concentration of polymer used for the formulation of solid dispersion. The result of dissolution study showed that Glibenclamide with PEG 4000 and PEG 1500 (F3 and F13) solid dispersion had faster dissolution rate than Glibenclamide itself.
